GlassScriptPhysician profile
Leland N Allen
NPI 1245258573
$2,857.34
in general payments reported to CMS, 2019-2025
28 companies · $357 in 2025
The $357 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,146 · 2020: $345 · 2021: $469 · 2022: $127 · 2023: $45.03 · 2024: $369 · 2025: $357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $614 · Education: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $613.78 |
| Education | $156.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $672.80 | 2019-2020 | |
| Abbvie INC. | $327.29 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $317.68 | 2019-2025 | Zerbaxa, Pifeltro, Dificid |
| Astellas Pharma US INC | $287.03 | 2019-2024 | Cresemba |
| Melinta Therapeutics, LLC | $239.52 | 2019-2025 | Rezzayo, Orbactiv, Kimyrsa |
| La Jolla Pharmaceutical Company | $203.61 | 2024-2025 | Xacduro, Zevtera |
| Novo Nordisk INC | $170.94 | 2020-2024 | Wegovy |
| Viiv Healthcare Company | $105.37 | 2019-2023 | Dovato |
| Gilead Sciences, INC. | $95.26 | 2019-2020 | |
| Amgen INC. | $46.60 | 2020 | |
| Amarin Pharma, INC. | $37.45 | 2020-2021 | |
| Pfizer INC. | $37.32 | 2025 | |
| Insmed, INC. | $33.20 | 2025 | Arikayce |
| Tetraphase Pharmaceuticals, INC. | $32.60 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $32.18 | 2024 | Airsupra |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $22.90 | 2025 | |
| Vifor Pharma, INC. | $21.37 | 2019 | |
| Fresenius USA Marketing, INC. | $20.92 | 2019 | |
| Lilly USA, LLC | $19.81 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $19.34 | 2019 | |
| Glaxosmithkline, LLC. | $18.88 | 2025 | Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $17.00 | 2022 | |
| Alexion Pharmaceuticals, INC. | $16.68 | 2022 | |
| Pulmonx Corporation | $16.26 | 2023 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.65 | 2020 | |
| Paratek Pharmaceuticals, INC. | $15.22 | 2024 | Nuzyra |
| Janssen Biotech, INC. | $14.46 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leland Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.